mug16 Antibody

What is MUC16 and why is it a promising therapeutic target?

MUC16 is a cell surface glycoprotein that is significantly overexpressed in multiple cancer types, particularly in ovarian cancer but also in substantial subsets of pancreatic and lung cancers. It plays an important role in tumorigenicity and acquired resistance to therapy . MUC16 functions as a protective barrier in normal physiology but contributes to disease progression and metastasis in several malignancies . Its aberrant overexpression in tumors, coupled with minimal expression in normal tissues, makes it an attractive target for cancer therapy . MUC16 modulates the innate immune response by inhibiting Natural Killer (NK) cell function, helping cancer cells evade host immune responses through mechanisms like down-regulation of CD16 on NK cells and inhibition of synapse formation between NK cells and cancer cells .

How should researchers account for MUC16 shedding when designing antibody-based experiments?

When designing experiments involving anti-MUC16 antibodies, researchers must account for the cleavage and shedding of the extracellular domain, which is a major barrier to efficient targeting of MUC16-expressing cancers . Most conventional anti-MUC16 antibodies are directed toward the extracellular domain (CA125), which is cleaved and shed into circulation, obscuring antibody accessibility to cancer cells .

Methodological approaches to address this issue include:

• Targeting the non-cleaved cell surface retained portion of MUC16, particularly the post-cleavage generated, surface-tethered MUC16 carboxy-terminal (MUC16-Cter) domain .

• Employing antibodies such as ch5E6, which targets the MUC16-Cter domain and has demonstrated efficacy in binding and interfering with MUC16-associated oncogenesis .

• Implementing parallel basic research to better understand MUC16 cleavage mechanisms and the functioning of the MUC16 cytoplasmic tail to develop more effective targeting strategies .

• Using antibodies like 5E6, 3H1, 2C6, and LUM16-4 that specifically target the carboxy-terminal region, which remains associated with the cell surface after extracellular domain shedding .

What are the critical differences between murine and human MUC16 that impact antibody development and testing?

Understanding the differences between murine Muc16 and human MUC16 is crucial when developing and testing MUC16 antibodies in mouse models. Key differences include:

• Expression pattern: While human MUC16 is expressed on the cell surface, murine Muc16 is primarily released from cells and is minimally detected on the cell surface of mouse ovarian cancer cells (MOVCAR) . Flow cytometry experiments consistently show high levels of intracellular Muc16 but little to no extracellular Muc16 expression on MOVCAR-10 cells .

• Molecular weight: Murine Muc16 is expressed as an approximately 250 kDa glycoprotein, which is substantially smaller than human MUC16 .

• Antibody recognition: Conventional anti-CA125 assays do not detect released murine Muc16. Researchers have identified specific antibodies (618F and 653F) that recognize both human MUC16 and murine Muc16, enabling comparative studies .

• Glycosylation: Like human MUC16, murine Muc16 carries both O-linked and N-linked oligosaccharides, but may have different glycosylation patterns .

These differences necessitate careful selection of antibodies for mouse model studies and consideration of the limitations in translating findings from murine models to human applications.

How do bispecific MUC16 antibodies function and what advantages do they offer over conventional antibody approaches?

Bispecific MUC16 antibodies represent an advanced approach to cancer immunotherapy by engaging two distinct targets simultaneously. Their mechanisms and advantages include:

• IMV-M (anti-MUC16/anti-DR5 bispecific antibody):

  • Functions through a novel mechanism of selectively binding and clustering death receptor 5 (DR5) upon engaging the tumor antigen MUC16 .

  • Achieves clustering by allowing multiple IMV-M molecules to bind to a single MUC16 molecule .

  • Demonstrates potent, MUC16-selective anti-tumor activity in vitro and in xenograft models without requiring secondary crosslinking .

  • Offers safety advantages over MUC16 antibody-drug conjugates (ADCs), which rely on cytotoxic payloads that limit their maximum tolerated dose .

• Ubamatamab (REGN4018, MUC16×CD3 bispecific antibody):

  • Bridges MUC16 on tumor cells and CD3 on T cells to promote T-cell-mediated cytotoxicity .

  • Can be combined with cemiplimab (anti-PD-1 antibody) to enhance MUC16×CD3 activity, as demonstrated in preclinical models .

  • Demonstrated an acceptable safety profile and durable clinical activity across a range of doses in Phase 1 trials for recurrent ovarian cancer .

These bispecific approaches overcome limitations of conventional antibody therapies by directly promoting tumor cell death through immune cell engagement or death receptor activation, rather than relying solely on Fc-mediated effector functions or internalization for payload delivery.

What mechanisms underlie the anti-tumor activity of antibodies targeting the MUC16 carboxy-terminal domain?

Antibodies targeting the MUC16 carboxy-terminal domain, such as the chimeric antibody ch5E6, offer distinct advantages and mechanisms of action:

• Targeting accessible epitopes: Unlike antibodies directed at the extracellular domain, which is cleaved and shed, ch5E6 targets the post-cleavage generated, surface-tethered MUC16 carboxy-terminal (MUC16-Cter) domain that remains accessible on cancer cells .

• Disruption of oncogenic signaling: ch5E6 binds and interferes with MUC16-associated oncogenesis by suppressing the downstream signaling pFAK(Y397)/p-p70S6K(T389)/N-cadherin axis .

• Targeting epithelial-to-mesenchymal transition (EMT): The robust clinical correlations observed between MUC16 and N-cadherin in patient tumors and metastatic samples suggest potential in targeting EMT, which is associated with disease aggressiveness .

• Multi-cancer efficacy: These antibodies demonstrate antiproliferative effects in cancer cells, 3D organoids, and tumor xenografts of both pancreatic cancer and non-small cell lung cancer, indicating broader applicability .

• Correlation with disease severity: The epitope expression of ch5E6 directly correlates with disease severity in pancreatic cancer and non-small cell lung cancer, suggesting potential utility as both a therapeutic and prognostic tool .

What experimental techniques are optimal for characterizing MUC16 antibody binding specificity and affinity?

Characterizing MUC16 antibody binding requires multiple complementary techniques to ensure comprehensive evaluation:

• Western blotting: Useful for detecting soluble forms of MUC16 and determining molecular weight. For example, antibodies 618F and 653F have been shown to detect an approximately 250 kDa band for murine Muc16, while standard anti-MUC16 antibodies like VK8 and OC125 may not detect murine variants .

• Flow cytometry: Essential for determining cell surface expression of MUC16 and antibody binding to intact cells. This technique revealed that 618F and 653F specifically bind to MUC16-positive OVCAR-3 cells but not to MUC16-negative SKOV-3 or CAOV-3 cells . It also demonstrated the primarily intracellular localization of murine Muc16 in MOVCAR cells .

• Size exclusion column chromatography: Valuable for isolating intact MUC16 produced by cells for further analysis, as used with MOVCAR cells .

• RT-PCR analysis: Used for detecting MUC16 mRNA expression to confirm transcription of the gene .

• ConA chromatography: Useful for determining the presence of N-linked oligosaccharides on MUC16 .

• Immunoassays: Different generations of immunoassays employ different antibody combinations for capture and detection. First-generation assays used OC125 for both, while second-generation assays used different monoclonal antibodies (OC125 as the conjugate antibody and M11 as the capture antibody) .

When interpreting binding data, researchers should consider that binding to MUC16 can be weaker compared to human MUC16 and may require appropriate antibody dilutions (e.g., 1:250 dilution for primary antibodies) .

How can researchers evaluate the therapeutic efficacy of MUC16 antibodies in preclinical models?

Evaluating therapeutic efficacy of MUC16 antibodies in preclinical models requires a multi-faceted approach:

• In vitro cytotoxicity assays: Measure direct antibody effects on MUC16-expressing cancer cell lines. The bispecific antibody IMV-M demonstrated potent, MUC16-selective anti-tumor activity in vitro without requiring secondary crosslinking .

• 3D organoid models: Provide a more physiologically relevant model than 2D cell cultures. The ch5E6 antibody demonstrated antiproliferative effects in 3D organoids of both pancreatic cancer and non-small cell lung cancer .

• Xenograft models: Essential for evaluating in vivo efficacy. Both IMV-M and ch5E6 have demonstrated anti-tumor activity in xenograft models .

• Signaling pathway analysis: Determines the mechanism of action by examining effects on oncogenic signaling pathways. For example, ch5E6 suppresses the downstream signaling pFAK(Y397)/p-p70S6K(T389)/N-cadherin axis .

• Toxicity studies: Critical for assessing safety. A pilot non-human primate toxicity study detected no toxicity with the bispecific antibody IMV-M .

• Pharmacokinetic analysis: Evaluates antibody distribution and metabolism. Ubamatamab demonstrated linear pharmacokinetics in phase 1 trials .

• Combination studies: Assess potential synergistic effects with standard-of-care drugs, as suggested for ch5E6 or with immune checkpoint inhibitors like cemiplimab for ubamatamab .

When evaluating murine models, researchers must account for the differences between human MUC16 and murine Muc16, particularly the limited cell surface expression of murine Muc16, which may affect the translatability of results to human applications .

What novel MUC16 antibody formats are being developed to overcome current therapeutic limitations?

Several innovative antibody formats are being developed to address the challenges in targeting MUC16:

• Bispecific antibodies with novel mechanisms:

  • IMV-M (anti-MUC16/anti-DR5) employs a unique clustering mechanism where multiple antibody molecules bind to a single MUC16 molecule, effectively inducing DR5 clustering and resulting in anti-tumor activity without requiring secondary crosslinking .

  • Ubamatamab (MUC16×CD3) bridges MUC16 on tumor cells and CD3 on T cells to promote T-cell-mediated cytotoxicity, representing a direct immunotherapeutic approach .

• Chimeric antibodies targeting specific domains:

  • ch5E6 targets the post-cleavage generated, surface-tethered MUC16 carboxy-terminal domain, avoiding the common problem of antibody binding being blocked by shed MUC16 .

• Combination approaches:

  • Pairing MUC16 antibodies with immune checkpoint inhibitors, as demonstrated by the combination of ubamatamab with cemiplimab (anti-PD-1) .

  • Evaluating MUC16-targeted antibodies with standard-of-care drugs to potentially augment treatment outcomes .

• Neo-antigen peptide vaccines:

  • While previous efforts to activate anti-MUC16 immune responses using anti-CA125 idiotype antibodies had limited success, neo-antigen peptide vaccines show promise for MUC16 immunotherapy .

These approaches represent significant advancements over conventional antibody strategies and address key limitations such as MUC16 shedding, off-target toxicity, and resistance mechanisms.

What are the key challenges in developing MUC16 antibodies that effectively distinguish between normal and malignant tissues?

Developing MUC16 antibodies that effectively distinguish between normal and malignant tissues faces several challenges:

• Shedding of the extracellular domain: The cleavage and shedding of MUC16's extracellular domain represents the major barrier for efficient targeting of MUC16-expressing cancers . Shed MUC16 in circulation can act as a decoy, reducing the effectiveness of antibodies targeting the extracellular domain .

• Understanding MUC16 cleavage mechanisms: Limited knowledge about the specific proteases and conditions that trigger MUC16 cleavage hampers the development of strategies to prevent shedding or to specifically target retained fragments .

• Cytoplasmic tail function: Incomplete understanding of the MUC16 cytoplasmic tail's role in oncogenesis limits the development of antibodies targeting this domain. Concerted efforts are needed to decipher the functioning of the MUC16 cytoplasmic tail .

• Tissue-specific expression patterns: While MUC16 is overexpressed in substantial subsets of ovarian, pancreatic, and lung cancers with minimal expression in normal tissues , developing antibodies that specifically recognize tumor-associated glycosylation patterns or conformational epitopes unique to cancer cells remains challenging.

• Species differences: Significant differences between human MUC16 and murine Muc16, including expression patterns and antibody recognition, complicate the translation of findings from mouse models to human applications . Unlike human MUC16, murine Muc16 is primarily released from cells rather than expressed on the cell surface .

Addressing these challenges requires multidisciplinary approaches combining basic research into MUC16 biology with innovative antibody engineering strategies to develop therapeutics that maximize efficacy while minimizing off-target effects.